4BIO Capital, a venture capital firm investing in advanced therapies in areas of high unmet medical need, appointed Abbas Hussain and Leszek Lisowski to its advisory board. Mr Hussain has over 30 years’ experience in the pharmaceutical industry, most recently as chief executive officer of Vifor Pharma. He also held senior executive positions at GSK Plc and worked in management at Eli Lilly and Co. Dr Lisowski has over 20 years’ experience in developing and manufacturing viral vectors. He was a co-founder of Nasdaq-listed gene therapy company LogicBio Therapeutics until October 2022 when the firm was acquired for $68 million by AstraZeneca Plc. He has also established two gene therapy companies in Australia, Exigen Biotherapeutics and Sendatu Therapeutics.
4BIO announced the appointments on 11 March 2024
Copyright 2024 Evernow Publishing Ltd